Cleared Traditional

THE PERCUTANEOUS NEPHROSTOLITHOTOMY DRAPE (K851675) - FDA 510(k) Clearance

Class II General Hospital device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K851675 · Lingeman Medical Products, Inc. · General Hospital
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
May 1985
Decision
21d
Days
Class 2
Risk

K851675 is an FDA 510(k) clearance for the THE PERCUTANEOUS NEPHROSTOLITHOTOMY DRAPE. Classified as Drape, Urological, Disposable (product code EYY), Class II - Special Controls.

Submitted by Lingeman Medical Products, Inc. (Indianapolis, US). The FDA issued a Cleared decision on May 14, 1985 after a review of 21 days - a notably fast clearance cycle.

This device falls under the General Hospital FDA review panel, regulated under 21 CFR 878.4370 - the FDA general hospital device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Lingeman Medical Products, Inc. devices

Submission Details

510(k) Number K851675 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received April 23, 1985
Decision Date May 14, 1985
Days to Decision 21 days
Submission Type Traditional
Review Panel General Hospital (HO)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
108d faster than avg
Panel avg: 129d · This submission: 21d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code EYY Drape, Urological, Disposable
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 878.4370
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most General Hospital devices follow this clearance model.